NASDAQ: AZTA
Azenta, Inc.CIK 0000933974 · SIC 3559 · Special Industry Machinery NEC
We are a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. We entered the life sciences market in 2011, leveraging our in-house precision automation and cryogenics capabilities that we were then applying in the… About this business →
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (DAL 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade AZTA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-K filed Nov 19, 2026 (period ending Sep 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Operations
(In thousands, except per share data)
| Description | Year ended September 30, 2026 | Year ended September 30, 2025 | Year ended September 30, 2024 |
|---|---|---|---|
| Revenue | |||
| Products | 165,291 | 173,189 | 173,717 |
| Services | 456,412 | 420,632 | 399,731 |
| Total revenue | 621,703 | 593,821 | 573,448 |
| Cost of revenue | |||
| Products | 95,850 | 94,894 | 105,446 |
| Services | 250,889 | 228,647 | 213,380 |
| Total cost of revenue | 346,739 | 323,541 | 318,826 |
| Gross profit | 274,964 | 270,280 | 254,622 |
| Operating expenses | |||
| Research and development | 37,918 | 30,390 | 31,524 |
| Selling, general and administrative | 257,526 | 261,563 | 262,958 |
| Impairment of goodwill and intangible assets | 149,083 | — | 4,658 |
| Restructuring charges | 5,136 | 5,171 | 6,766 |
| Total operating expenses | 449,663 | 297,124 | 305,906 |
| Operating loss | (174,699) | (26,844) | (51,284) |
| Other income (expense) | |||
| Interest income, net | 17,830 | 18,779 | 32,891 |
| Other income (expense), net | 5,863 | 922 | (732) |
| Loss from continuing operations before income taxes | (151,006) | (7,143) | (19,125) |
| Income tax expense (benefit) | 6,860 | (31,601) | 5,241 |
| (Loss) income from continuing operations | (157,866) | 24,458 | (24,366) |
| Loss from discontinued operations, net of tax | (9,119) | (80,221) | (140,531) |
| Net loss | (166,985) | (55,763) | (164,897) |
| Basic net income (loss) per share: | |||
| (Loss) income from continuing operations | (3.50) | 0.53 | (0.46) |
| Loss from discontinued operations, net of tax | (0.20) | (1.75) | (2.64) |
| Net loss per share | (3.70) | (1.22) | (3.10) |
| Diluted net income (loss) per share: | |||
| (Loss) income from continuing operations | (3.50) | 0.53 | (0.46) |
| Loss from discontinued operations, net of tax | (0.20) | (1.75) | (2.64) |
| Diluted net loss per share | (3.70) | (1.22) | (3.10) |
| Weighted average shares used in computing net income (loss) per share: | |||
| Basic | 45,130 | 45,743 | 53,175 |
| Diluted | 45,130 | 45,896 | 53,175 |
Consolidated Balance Sheets
(In thousands, except share and per share data)
| Description | September 30, 2026 | September 30, 2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | 193,798 | 279,783 |
| Short-term marketable securities | 138,886 | 61,137 |
| Accounts receivable, net of allowance for expected credit losses ($4,111 and $4,649, respectively) | 143,418 | 142,181 |
| Inventories | 77,122 | 74,956 |
| Short-term restricted cash | 265 | 2,359 |
| Refundable income taxes | 10,717 | 9,728 |
| Contract assets | 32,971 | 37,295 |
| Prepaid expenses and other current assets | 26,359 | 27,365 |
| Current assets held for sale | — | 73,535 |
| Total current assets | 623,536 | 708,339 |
| Property, plant and equipment, net | 175,245 | 153,954 |
| Long-term marketable securities | 169,200 | 201,585 |
| Long-term deferred tax assets | 499 | 726 |
| Operating lease right-of-use assets | 59,012 | 54,048 |
| Goodwill | 546,259 | 702,395 |
| Intangible assets, net | 79,998 | 101,814 |
| Long term income taxes receivable | 45,600 | 45,600 |
| Other assets | 9,034 | 6,115 |
| Noncurrent assets held for sale | — | 85,006 |
| Total assets | 1,708,383 | 2,059,582 |
| Liabilities and stockholders' equity | ||
| Current liabilities | ||
| Accounts payable | 55,219 | 37,722 |
| Deferred revenue | 40,081 | 31,569 |
| Derivative liability | 25,641 | 33,420 |
| Accrued warranty and retrofit costs | 3,544 | 4,713 |
| Accrued compensation and benefits | 33,396 | 35,799 |
| Customer deposits | 33,566 | 26,499 |
| Accrued income taxes payable | 3,517 | 9,416 |
| Accrued expenses and other current liabilities | 38,123 | 30,268 |
| Current liabilities held for sale | — | 28,268 |
| Total current liabilities | 233,087 | 237,674 |
| Long-term deferred tax liabilities | 15,338 | 18,245 |
| Long-term operating lease liabilities | 51,874 | 51,244 |
| Other long-term liabilities | 10,863 | 11,142 |
| Noncurrent liabilities held for sale | — | 14,291 |
| Total liabilities | 311,162 | 332,596 |
| Stockholders' equity | ||
| Preferred stock, $0.01 par value 1,000,000 shares authorized, no shares issued or outstanding | — | — |
| Common stock, $0.01 par value 125,000,000 shares authorized, 55,284,062 shares issued and 41,757,019 shares outstanding at September 30, 2026, 59,320,848 shares issued and 45,858,979 shares outstanding at September 30, 2025 | 553 | 594 |
| Additional paid-in capital | 424,268 | 529,605 |
| Accumulated other comprehensive loss | (77,398) | (22,213) |
| Treasury stock, at cost 13,527,043 shares at September 30, 2026 and 13,461,869 shares at September 30, 2025 | (203,173) | (200,956) |
| Retained earnings | 1,252,971 | 1,419,956 |
| Total stockholders' equity | 1,397,221 | 1,726,986 |
| Total liabilities and stockholders' equity | 1,708,383 | 2,059,582 |
Consolidated Statements of Cash Flows
(In thousands)
| Description | Year ended September 30, 2026 | Year ended September 30, 2025 | Year ended September 30, 2024 |
|---|---|---|---|
| Cash flows from operating activities | |||
| Net loss | (166,985) | (55,763) | (164,897) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||
| Depreciation and amortization | 56,520 | 61,209 | 90,744 |
| Impairment of goodwill and intangible assets | 149,083 | — | 115,975 |
| Non-cash gain from settlement of preexisting contractual relationship | (3,716) | — | — |
| Loss on assets held for sale | 9,491 | 93,118 | — |
| Property, plant and equipment and other asset write-offs | 1,363 | 3,478 | 4,430 |
| Inventory write-downs | 4,015 | — | 3,290 |
| Other non-cash adjustments | (1,985) | — | 4,317 |
| Stock-based compensation | 12,243 | 20,881 | 14,467 |
| Amortization and accretion on marketable securities | (1,424) | (1,578) | (6,032) |
| Deferred income taxes | (5,170) | (27,038) | (15,886) |
| Loss on disposals of property, plant and equipment | 14 | 711 | 296 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | 4,423 | 21,039 | (12,067) |
| Inventories | (8,041) | (2,671) | 15,896 |
| Accounts payable | 12,662 | 1,037 | 9,196 |
| Deferred revenue | 6,020 | 641 | (3,558) |
| Accrued warranty and retrofit costs | (424) | (435) | (684) |
| Accrued compensation and tax withholdings | (1,418) | 7,427 | (2,754) |
| Long term income taxes receivable | — | (45,600) | — |
| Other assets and liabilities | (9,165) | (4,275) | (2,990) |
| Net cash provided by operating activities | 57,506 | 72,181 | 49,743 |
| Cash flows from investing activities | |||
| Purchases of property, plant and equipment | (30,079) | (33,857) | (37,392) |
| Purchases of marketable securities and other investments | (375,684) | (451,409) | (405,575) |
| Sales and maturities of marketable securities | 328,609 | 389,452 | 666,230 |
| Acquisition of UK Biocentre, net of cash acquired | (11,150) | — | — |
| Proceeds from other investment | — | 2,130 | — |
| Net investment hedge settlement | — | 3,223 | 1,476 |
| Proceeds from the sale of B Medical Systems business, net of cash transferred | 54,503 | — | — |
| Net cash (used in) provided by investing activities | (33,801) | (90,461) | 224,739 |
| Cash flows from financing activities | |||
| Proceeds from issuance of common stock | 2,204 | 2,770 | 3,279 |
| Payments of finance leases | (748) | (985) | (783) |
| Withholding tax payments on net share settlements on equity awards | (2,669) | — | — |
| Share repurchases | (118,286) | — | (661,703) |
| Excise tax payment for settled share repurchases | — | (11,376) | — |
| Net cash used in financing activities | (119,499) | (9,591) | (659,207) |
| Effects of exchange rate changes on cash, cash equivalents and restricted cash | (2,576) | 3,566 | 21,670 |
| Net decrease in cash, cash equivalents and restricted cash | (98,370) | (24,305) | (363,055) |
| Cash, cash equivalents and restricted cash, beginning of period | 296,685 | 320,990 | 684,045 |
| Cash, cash equivalents and restricted cash, end of period | 198,315 | 296,685 | 320,990 |
| Supplemental disclosures: | |||
| Cash paid for income taxes, net | 18,118 | 6,568 | 2,704 |
| Purchases of property, plant and equipment included in accounts payable and accrued expenses | 9,404 | 5,546 | 2,767 |
Amounts as printed on the EDGAR/iXBRL face — (In thousands, except per share data); (In thousands, except share and per share data); (In thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗
About Azenta, Inc.
Source: Item 1 (Business) from the 10-K filed November 19, 2026. Description as filed by the company with the SEC.
Item 1. Business
Overview
We are a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. We entered the life sciences market in 2011, leveraging our in-house precision automation and cryogenics capabilities that we were then applying in the semiconductor manufacturing market. This led us to develop and provide solutions for automated ultra-cold storage. Since then, we have expanded our life sciences offerings through internal investments and through a series of acquisitions. We support our customers from research and clinical development to commercialization with our sample management and automated storage systems, as well as genomic services expertise to help our customers bring impactful therapies to market faster. We understand the importance of sample integrity and offer a broad portfolio of products and services supporting customers at every stage of the life cycle of samples, including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software, along with sample repository services. Our expertise, global footprint, and leadership positions enable us to be a trusted global partner to pharmaceutical, biotechnology and life sciences research institutions. In total, we employ approximately 2,850 full-time employees, part-time employees and contingent workers worldwide as of September 30, 2026 and have sales in approximately 87 countries. We are headquartered in Burlington, Massachusetts and have operations in North America, Asia and Europe.
Read full description ↓
Our Company was founded in 1978 and became a leading automation provider and partner to the global semiconductor manufacturing industry. We divested the last of our semiconductor businesses in February 2022 for $2.9 billion in cash and since then operate solely as a life sciences company. On December 1, 2021, we changed our corporate name from “Brooks Automation, Inc.” to “Azenta, Inc.” and our common stock started to trade on the Nasdaq Global Select Market under the symbol “AZTA”. We divested our B Medical Systems business in July 2026 for $63.0 million in cash. This strategic action simplified our portfolio and allowed management to focus on driving revenue growth and profitability in our core Sample Management Solutions and Multiomics segments. Both the semiconductor automation results and the B Medical Systems business results are classified as discontinued operations, and, unless otherwise noted, the description of our business in this Annual Report on Form 10-K relates solely to our continuing operations.
Our portfolio includes product and service offerings developed by us internally, as well as obtained through acquisitions, designed to provide comprehensive capabilities to our customers, addressing their needs in sample exploration and management, automated storage and multiomics. We continue to develop new product and service offerings and enhance existing and acquired offerings through the expertise of our research and development resources. We believe our acquisition, investment, and integration approach has allowed us to accelerate internal development and significantly accelerate time to market for our life sciences solutions.
For further information on our acquisitions, please refer to Note 4, Business Combinations to our consolidated financial statements included under Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K.
Recent Developments
Leadership Transition
On August 22, 2026, John P. Marotta resigned as our President and Chief Executive Officer and as a director, and our Board of Directors appointed Dr. Martin D. Madaus, a member of the Board since January 2024, as Interim President and Chief Executive Officer. The Board has retained an executive search firm, and a search for a permanent Chief Executive Officer is underway.
Multiomics Restructuring Plan
On October 5, 2026, our Board of Directors approved, and we committed to, a restructuring plan within our Multiomics segment intended primarily to consolidate our North American laboratory network, simplify our organizational structure and improve operating efficiency. The plan consists of workforce reductions and the closure of three of our Multiomics laboratory sites in North America. We currently estimate aggregate pre-tax charges of approximately $11.0 million to $13.0 million, consisting primarily of approximately $9.0 million of asset impairment charges and approximately $3.0 million of employee severance and other restructuring charges, substantially all of which we expect to recognize in fiscal year 2027, and we expect to substantially complete the planned actions by March 31, 2027, subject to applicable
legal and employee notice and consultation requirements. We expect the plan to generate approximately $11.0 million of annualized cost savings once fully implemented. Actual charges, timing and savings may differ materially from these estimates.
Gene Synthesis Investments
On October 28, 2026, we acquired SynPlexity Inc. (“SynPlexity”), a DNA assembly technology company providing products and services centered on large, multiplexed gene libraries, and entered into an exclusive, royalty-free technology license agreement and a master services and supply agreement with Elegen Corp. (“Elegen”) relating to Elegen’s cell-free DNA synthesis technology. We intend to integrate these technologies into our Multiomics segment’s gene synthesis portfolio.
We acquired SynPlexity for a base purchase price of $15.0 million in cash, of which approximately $2.5 million was held back, subject to customary closing and post-closing adjustments. The purchase agreement also provides for contingent consideration of up to $10.0 million based on the achievement of a specified revenue milestone through September 30, 2029. Due to the timing of the acquisition, the initial accounting for the business combination is incomplete, and certain disclosures related to the acquisition are not yet available.
Under the license agreement with Elegen, the license has an initial five-year term and requires fixed license payments totaling $23.0 million, subject to certain retained rights and exceptions in favor of Elegen. We have an option, exercisable between 12 and 18 months after execution, to convert the license into an irrevocable, perpetual, exclusive, royalty-free license for $25.0 million, plus any then-unpaid license fees, subject to the license’s term. We currently expect aggregate capital deployment under the Elegen arrangements to range from approximately $32.0 million to approximately $71.0 million, depending on the extent of our future capital equipment purchases and whether we exercise the conversion option.
Life Sciences Market
Our businesses serve a broad range of end markets within the life sciences industry to help our customers advance the development of therapies to improve people’s lives and cure diseases. With the advent of biologics and personalized medicine, biological samples have become critical assets to the success of drug and therapy pipelines, and the proper management and protection of these samples are important to our customers. As a result, we believe there is a sizable market opportunity for us to provide comprehensive sample management and genomic solutions.
Since the successful mapping of the full human genome at the turn of this century, the market for genomic services has grown in support of research in biologic drug development, personalized medicine, and cell and gene therapy, or CGT. Pharmaceutical and biotechnology companies and institutions may use their in-house laboratory resources to sequence millions of genes as part of their research workflows. Many companies and institutions outsource all or a part of their gene sequencing to independent laboratories that provide expedited results and expert consultation services. We participate in this market as a value-added laboratory services provider, offering high quality genetic testing services with fast turnaround times and expert customer support.
We have approximately 11,000 customers globally and believe we are well positioned to expand our customer base. We serve top pharmaceutical and biotechnology companies, the most advanced research hospitals performing clinical research and therapy development, as well as some of the newest and leading-edge start-ups in the biotech space. In addition, we serve academic and government institutions. Demand varies by offering and region; for example, in fiscal year 2026, revenue from Sample Repository Services and Consumables and Instruments increased, while revenue from Automated Stores and Sanger sequencing services declined. See Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Segments
Our operating and reportable segments consist of the following:
•Sample Management Solutions. The Sample Management Solutions business resources operate as a single business unit offering end-to-end sample management products and services, including Sample Repository Services, or SRS, and Core Products (Automated Stores, Cryogenic Systems, Automated Sample Tube, Consumables and Instruments and Controlled Rate Thawing Devices).
•Multiomics. The Multiomics business resources operate as a single business unit offering genomic and other sample analysis services, including gene sequencing, gene synthesis and related services.
For further information on our reportable and operating segments, please refer to Note 18, Segment and Geographic Information to our consolidated financial statements included under Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10‑K.
Sample Management Solutions
Within our Sample Management Solutions segment, we operate as a single business unit offering end-to-end sample management products and services, including SRS and Core Products (Automated Stores, Cryogenic Systems, Automated Sample Tube, Consumables and Instruments and Controlled Rate Thawing Devices). This portfolio provides customers with a high level of sample quality, security, availability, intelligence and integrity throughout the lifecycle of samples, providing customers with complete end-to-end “cold chain of custody” capabilities. We also offer expert-level consultation services to our clients throughout their experimental design and implementation processes.
SRS – Our SRS services include a complete range of services consisting of on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions (inclusive of sample preparation and laboratory-based sample analysis), disaster recovery and business continuity, and project management and consulting. Our informatics solutions provide sample intelligence software solutions, and support laboratory workflow scheduling for life science tools and instrument work cells, sample inventory and logistics, environmental and temperature monitoring, clinical trial and consent management, and planning, data management, virtualization, and visualization of sample collections. We offer enhanced on-site and off-site management of biological sample inventories and integration solutions to our customers for their increasingly distributed workflows.
Automated Stores – Our automated stores product includes stand-alone systems that can store over 20 million samples in temperature ranges from ambient to -80°C. Our automated stores have a unique design that allows controlled temperature storage down to -80°C with the industry’s highest throughput of sample retrieval. Our automated stores provide high throughput capability and optimized storage of multi-format tubes and plates while maintaining consistent temperature profiles across stored samples. We also offer a portfolio of services designed to optimize the productivity of our automated storage offerings.
Cryogenic Systems – Our cryogenic systems provide cryogenic storage ranging from high efficiency LN2 vapor-based cryogenic freezers to fully automated systems that preserve sample integrity and chain of custody, as well as the storage materials needed to keep samples safe during every step of the cold chain. Our cryogenic systems provide long-term cryogenic storage with accurate record-keeping and dependable temperature control, even during transport. The systems combine well-documented sample protection and comprehensive inventory management with superior user experience and enable our customers to plan a scalable cryogenic infrastructure to maintain quality and documentation.
Automated Sample Tubes – Our automated sample tube product offerings include a range of automation-friendly storage tubes with coding options such as 2D-coded, dual-coded, and tri-coded, with either external or internal threading, and instruments for faster reading, capping, and de-capping.
Consumables and Instruments – Our consumables and instruments products include a complete range of consumables, including multiple formats of racks, tubes, caps, plates and foils, which are used for storage and handling of samples in ambient to ultra-cold storage environments. A comprehensive range of instruments used for labeling, bar coding, capping, de-capping, auditing, sealing, peeling, and piercing tubes and plates complement our consumables. Our offerings include a range of products aimed at the genomic sample preparation and services market for polymerase chain reaction, or PCR, and sequencing, imaging, synthesizing, liquid handling, and sample processing.
Controlled Rate Thawing Devices – Our controlled rate thawing devices include a range of products for automated thawing of plasma, blood and stem cells as well as in CGT applications. Our products are used for controlled rate thawing of cryopreserved samples and therapies, and are used in research and development, clinical trials, good manufacturing practices and in the hospital setting.
Multiomics
Within our Multiomics segment, our genomic services business advances research and development activities by providing gene sequencing, synthesis, and related services. We offer a comprehensive, global portfolio that we believe has broad appeal in the life sciences industry and enables customers to select the best solution for their research and development challenges. This portfolio also offers unique solutions for key markets such as CGT, antibody development, and biomarker discovery by addressing genomic complexity and throughput challenges. In October 2026, we acquired SynPlexity, which provides pooled gene assembly technology for large, multiplexed gene libraries, and obtained an
exclusive license to Elegen’s cell-free DNA synthesis platform, each of which we intend to integrate into our gene synthesis portfolio. See “Recent Developments” above.
Genomic Services – Our genomic services business includes gene sequencing and gene synthesis services, enabling the expanding research and development of gene-based healthcare discoveries and therapies. These service offerings include Next-Generation sequencing, or NGS, Sanger sequencing, gene synthesis, bioinformatics, and good laboratory practices, or GLP, regulatory services. The sequencing services are available with both standard and custom services for extraction, library preparation, sequencing, and bioinformatics, supported by Ph.D.-level project managers providing consultation services, updates, and post-delivery assistance. Our gene synthesis offerings provide production of a wide range of sequence lengths and structural complexity, DNA cloning, gene fragment synthesis, oligo synthesis, antibody production, viral packaging services, and plasmid purification.
Sales, Marketing and Customer Support
Most of our sales are completed through our direct sales force, particularly our automated storage systems, storage services, and genomic services. We supplement the sale of consumables and instruments with distributors that reach a broad range of customers. In regions with emerging life sciences industries, we leverage local distributors to assist with the sales process.
The sales process for our SRS and larger automated storage systems takes months to complete and may involve a team from sales, marketing, and engineering. Sales of genomic services are generally generated through online orders from customer laboratories and are delivered to and from customers using courier services, with the simplest genomics and synthesis requests completed in less than 24 hours and more complex projects within weeks.
Participation in trade shows, seminars, and industry forums is just one of our marketing initiatives. We also produce and distribute sales brochures, webinars, and white papers, and we publish press releases and articles in business and industry publications. We maintain sales and service centers in Asia, Europe, the Middle East, and North America to enhance support of, and communication with, customers.
We typically provide product warranties for a period of up to five years depending on the product type. Customer support capabilities include utilization of offsite technicians and in-country support provided by our own employees and local contractors.
Competition
Given the breadth of the solutions and services offered by our Sample Management Solutions and Multiomics segments, we believe we have a unique portfolio of products and services. Each segment, however, faces unique competitors within its respective market offerings. In the Sample Management Solutions segment, our main competitors include Hamilton Company and Liconic AG for automation systems and Laboratory Corporation of America Holdings and Thermo Fisher Scientific Inc. for storage, consumables and services. In the Multiomics segment, our main competitors include BGI Genomics Co., Ltd., Eurofins Scientific S.E., GenScript Biotech Corporation, Integrated DNA Technologies, Inc., Novogene Co., Ltd., and Twist Bioscience Corporation.
Research and Development
Our research and development efforts are focused on developing new products and enhancing the functionality, degree of integration, reliability and performance of our existing products and service offerings. Our engineering, marketing, operations, and management personnel leverage their close collaborative relationships with their counterparts in customer organizations to proactively identify market demands that help us refocus our research and development investments to match our customers’ demands.
We have developed and continue to develop automated biological sample storage solutions for operating in ultra-low temperature environments. Our portfolio includes automated stores and cryogenic systems operating from ambient temperatures to -190°C. Our automated storage systems offer improved data management and sample security for vaccines and biologics and have a unique design, which allows controlled temperature storage down to -80°C with the industry’s highest throughput of sample retrieval. Our genomic services advance research and development activities in gene sequencing, synthesis, and related services to meet market demands. We invest in developing protocols and improving efficiencies in our laboratories to provide proprietary offerings to our customers. For example, in our Multiomics segment, we enriched our portfolio by adding regulated services targeting the analysis of adeno-associated virus, a common vector used in CGT. Furthermore, we continue to add value to drug discovery and development research by expanding our
portfolio to include proteomics solutions, antibody production, and viral packaging services. We will continue to focus on developing processes and technologies that can streamline sample-to-data workflows.
Manufacturing and Services
Our manufacturing operations include product assembly, integration, and testing. We implement quality assurance procedures that include standard design practices, reliability testing and analysis, supplier and component selection procedures, vendor controls, manufacturing process controls, and service processes that ensure high-quality performance of our products. Our major manufacturing facilities are in Missouri, United States, and in Manchester and Wotton, United Kingdom. Our manufacturing operations are designed to provide high-quality, cost-effective, differentiated products to our customers with short lead times through responsive and flexible manufacturing processes and sourcing strategies. We utilize lean manufacturing techniques throughout our operations.
We have service and support locations near our customers to provide rapid response to their service needs. Our principal product service and support locations include Burlington, Massachusetts, and Manchester, United Kingdom.
We provide sample management storage and transportation services in Billerica, Massachusetts; Indianapolis and Plainfield, Indiana; Fresno, California; Cleveland, Ohio; Griesheim, Germany; Montreal, Canada; Singapore; and Beijing, China. As of September 30, 2026, we had a network of 12 laboratories that provide genomic services, including five in the United States, three in China, two in the United Kingdom, and one each in Japan and Germany. In March 2026, we acquired UK Biocentre, which provides sample management, sample storage and high-throughput sample processing services in Milton Keynes, the United Kingdom. Under the restructuring plan approved on October 5, 2026, we expect to close three of our Multiomics laboratory sites in North America by March 31, 2027.
Patents and Proprietary Rights
We rely on patents, trade secret laws, confidentiality agreements and procedures, copyrights, trademarks and licensing agreements to protect our technology. Due to the rapid technological change that characterizes the life sciences and related process equipment industries, we believe that the improvement of existing technology, reliance upon trade secrets, unpatented proprietary know-how, and the development of new products and services may be as important as patent protection in establishing and maintaining a competitive advantage. Our policy is to require all employees to enter into proprietary information and nondisclosure agreements to protect trade secrets and know-how. We cannot guarantee, however, that these efforts will meaningfully protect our trade secrets.
We own issued patents and have pending patent applications in the United States and other jurisdictions relating to various aspects of our products, services and technologies. These patents and applications relate principally to automated and cryogenic sample storage and retrieval systems and methods; sample tubes, plates, seals and other laboratory consumables; sample identification, capping, decapping and handling equipment and methods; sample freezing and temperature-control equipment; and certain molecular biology methods and reagents. Our issued patents are expected to expire at various dates from 2027 through 2044, assuming payment of applicable maintenance fees and annuities and without taking into account any patent term extensions. We do not consider any single patent or group of related patents to be material to our business as a whole.
Environmental Matters and Government Regulations
Environmental Regulations
We are subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the United States and other countries. Federal environmental legislation in the United States that affects us includes the Resource Conservation and Recovery Act, the Clean Air Act, the Clean Water Act, the Safe Drinking Water Act, and the Comprehensive Environmental Response Compensation and Liability Act. We are also subject to regulation by the Occupational Safety and Health Administration, or OSHA, concerning employee safety and health matters. The United States Environmental Protection Agency, or the EPA, OSHA, and other federal agencies have the authority to promulgate regulations that have an effect on our operations.
In addition to these federal laws and regulations, various states have been delegated certain authority under the federal statutes and have authority over these matters under state laws. Many state and local governments have adopted environmental and employee safety and health laws and regulations, some of which are similar to federal requirements. The foreign jurisdictions in which we operate have also adopted similar laws and regulations.
Biotechnology Procurement, Data Security and Biosecurity
In December 2025, the BIOSECURE Act was enacted as Section 851 of the National Defense Authorization Act for Fiscal Year 2026. Subject to phased implementation, including publication by the Office of Management and Budget of an initial list of “biotechnology companies of concern” by December 2026, followed by implementing guidance and amendments to the Federal Acquisition Regulation, the law restricts U.S. executive agencies from procuring biotechnology equipment or services from designated companies and from contracting with entities that use such equipment or services in the performance of federal contracts. Our genomic services and related data flows are also subject to the U.S. Department of Justice rule restricting access to bulk U.S. sensitive personal data, including human’omic data, by countries of concern and covered persons (28 C.F.R. Part 202). In addition, Executive Order 14292, issued in May 2025, directed federal agencies to revise or replace the federal framework for screening synthetic nucleic acid orders and to require federally funded purchasers to obtain synthetic nucleic acids only from providers that adhere to the updated framework. Our genomic services operations in China are subject to Chinese laws governing human genetic resources, data security and cross-border data transfers. We maintain biosecurity screening processes for synthetic nucleic acid orders, including sequence screening under International Gene Synthesis Consortium guidelines and customer and end-use review, and have implemented controls intended to prevent prohibited transfers of U.S. human’omic data to China, including procedures designed to prevent U.S. human-derived samples from being transferred there for processing. These controls will require continued review and enhancement as applicable procurement, biosecurity, data-security and Chinese regulatory requirements evolve, and changes in those requirements or their application to our operations could require additional system, workflow or capacity changes, increase costs, impact the time it takes to deliver services, or limit our ability to serve certain customers or participate in federally funded work.
Other Laws and Regulations
Our operations are also subject to other government regulations in the United States and the other countries in which we operate and conduct business. While most of our products are not regulated, certain products in our Sample Management Solutions segment are regulated by the FDA under the Federal Food, Drug, and Cosmetic Act, which could result in additional compliance costs, delays in product launches, or potential recalls if standards are not met. Our GLP regulatory services in our Multiomics business require accreditation and certification of the laboratories in which we perform those services and failure to maintain such accreditations could lead to loss of customer contracts or regulatory penalties.
Our businesses also include export and import activities, which are subject to pertinent laws enforced by the U.S. Departments of Commerce, State, and Treasury. In addition, our logistics activities must comply with the rules and regulations of the Department of Transportation, the Federal Aviation Administration, and similar foreign agencies.
We believe we are in compliance in all material respects with all applicable environmental, employee health and safety and other government regulations, and such compliance has not had, and is not expected to have, an adverse effect on our capital expenditures, competitive position, financial condition, or results of operations.
Human Capital
In total, we employ approximately 2,850 full-time employees, part-time employees and contingent workers worldwide as of September 30, 2026, primarily in the United States. We understand that our success depends on our highly talented associates, and our human capital management practices focus on attracting and retaining a diverse and engaged workforce.
Employee Engagement, Workplace Inclusion and Belonging
We are committed to fostering a culture and environment where every employee feels valued. Our success depends in large part on our hiring and retaining top talent across the entire organization, with primary emphasis on our management team and our employees who interface directly with our customers. We compete for talent with other companies both smaller and larger, and both in our market and in other industries. We strive to attract, develop, and retain diverse talent that is inclusive of every age, gender, gender identity, race, sexual orientation, physical capability, neurological difference, ethnicity, belief, and perspective. Our goal is to develop cultural competency by seeking knowledge, increasing awareness, developing sensitivity, modeling respect, and promoting inclusion and unity. Approximately 48% of our employees are gender diverse, and 40% of our U.S.-based employees identify as being racially diverse. Additional details on our gender and racial diversity can be found on our website in our environmental, social, and governance, or ESG, governance reports.
Compensation and Benefits
To attract and retain top talent, we focus on having a diverse, inclusive, and safe workplace, while offering competitive compensation, benefits, and health and wellness programs. A majority of our employees also have incentive compensation opportunities, which are primarily focused on meeting financial, sales, operational, and/or customer focused metrics. In addition, our long-term equity compensation is intended to align management interests with those of our stockholders and to encourage the creation of long-term value.
Training and Development
We provide training and learning opportunities, rotational assignment opportunities, and continuous performance feedback to further our employee development. Our learning culture is built on formal curriculums, communities of practice, peer-to-peer learning, experiential development, support tools, and ongoing assessment. We listen to our employees to better understand their training and development needs, and ensure our offerings cater to both technical learning and leadership development.
Employee Health and Safety
Compliance with environmental, health and safety, or EH&S, laws and regulations underlies the basis of the EH&S programs we have in place. As part of our EH&S programs, we:
•help build a culture of safety that emphasizes safe operations, procedures, behaviors, and attitudes;
•provide compliance training on general safety principles and job-specific requirements;
•equip employees to recognize and execute their responsibilities for safety through numerous training events;
•provide appropriate personal protective equipment and training in the safe use of that equipment;
•help ensure all employees are aware of their surroundings and that everyone works to maintain a safe workplace;
•hold recurring, regular corporate-wide safety committee meetings for employees at all levels, including executive management; and
•support employees to conduct job hazard analysis with the purpose of recognizing workplace hazards and reducing risk.
Purpose and Core Values
Our Company Purpose is to enable life sciences organizations around the world to bring impactful therapies to market faster. We are committed to making sure that every team member understands our core values of Customer Focus, Achievement, Accountability, Teamwork, Employee Value, and Integrity. These core values are the foundation from which we act and base our decisions and are embodied in our Standards of Conduct, which outline our commitment to our customers, our investors, our communities, and to one another. Our Standards of Conduct also outline what we expect of our employees and ensure we continue to foster a culture of high integrity. We adhere to the governance requirements established by federal and state law, the SEC, and the Nasdaq Global Select Market, and we strive to establish appropriate risk management methods and control procedures to adequately manage, monitor, and control the major risks we may face day to day and year to year.
Available Information
We file annual, quarterly, and current reports, proxy statements, and other information with the SEC. Our SEC filings are available to the public over the internet at the SEC’s website at http://www.sec.gov. We also maintain a website at www.azenta.com, through which you can access our SEC filings and copies of our press releases as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The information found on our website is not part of this or any other report we file with, or furnish to, the SEC.